| Disease | IN A RANDOMIZED OPEN AND PLACEBO-CONTROLLED CLINICAL TRIAL INCLUDING 48 PATIENTS WITH VASCULAR DEMENTIA, THE EFFECTS OF INFUSIONS OF THE GINKGO BILOBA SPECIAL EXTRACT EGB 761 AT DOSES OF 50, 100 AND 200 MG WERE INVESTIGATED AS AGAINST PLACEBO
INFUSIONS. FOR THIS PURPOSE, THE 48 PATIENTS WERE RANDOMLY ALLOTED TO 4 GROUPS WITH GROUP I RECEIVING PLACEBO, GROUP 11 50 MG EGB 761, GROUP III 100 MG EGB 761 AND GROUP IV 200 MG EGB 761. PRIMARY VARIABLES CHOSEN WERE MICROPERFUSION OF THE SKIN
AS WELL AS WHOLE-BLOOD VISCOSITY AND ELASTICITY. THE VALUES WERE DETERMINED PREVIOUS TO THE BEGINNING OF THE INFUSION AND THEN 10, 20, 30. 45, 80 AND 120 MINUTES LATER; MICROPERFUSION OF THE SKIN WAS ADDITIONALLY MEASURED 5 MINUTES AFTER THE
BEGINNING OF THE INFUSION. NO STATISTICALLY SIGNIFICANT DIFFERENCES WERE FOUND BETWEEN GROUP I (PLACEBO AND GROUP II (50 MG EGB 761) AS CONCERNS MICROPERFUSION. THE COMPARISON BETWEEN GROUP III (100 MG EGB 761) AND GROUP IV (200 MG EGB 761)
SHOWED SINGIFICANT DIFFERENCES AFTER 45 AND 120 MINUTES IN FAVOR OF THE HIGHER DOSE. FURTHERMORE, IT WAS POSSIBLE TO DEMONSTRATE AN INCREASE IN MICROPERFUSION IN GROUPS III AND IV WHICH WAS SIGNIFICANT AS COMPARED TO GROUP I FROM 20 AND 30
MINUTES AFTER INFUSION OVER A PERIOD OF 120 MINUTES. WHOLE-BLOOD VISCOELASTICITY ALSO SHOWED DOSE-DEPENDENT CHANGES WITH STATISTICALLY SIGNIFICANT DIFFERENCES BETWEEN GROUP IV AND GROUP 1 AFTER 60 MINUTES AS WELL AS BETWEEN GROUP IV AND GROUP
II AFTER 45 MINUTES IN EACH CASE IN FAVOR OF THE HIGHER DOSE. THE INCREASE IN PERFUSION IN GROUP IV WAS MUCH HIGHER THAN FIRST GROUP(I) AND GROUP II (P>0.05 RESPECTIVELY.
A COMMERCIAL PRODUCT, EGB-761, WAS USED. |